UBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Pre-Open Stock Movers 10/29: (LOCK) (HBI) (AGN) Higher; (STRP) (AFOP) (NXPI) Lower (more...)October 29, 2015 9:32 AM After-Hours Stock Movers 10/28: (LOCK) (HBI) (SPWR) Higher; (AFOP) (GPRO) (BWLD) Lower (more...)October 28, 2015 6:33 PM Amgen (AMGN) Tops Q3 EPS by 35c; Raises OutlookOctober 28, 2015 4:03 PM Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72October 28, 2015 4:01 PM Amgen (AMGN) Announces FDA Approval of IMLYGICOctober 27, 2015 4:54 PM FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The USOctober 27, 2015 4:46 PM Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF DataOctober 27, 2015 2:52 PM Trading Radar for 10/28: GoPro (GPRO), Walgreens Boots (WBA), Western Digital (WDC), Marriott (MAR) ReportOctober 27, 2015 2:35 PM Amgen (AMGN), Cytokinetics (CYTK) Announce Statistically Significant Data from COSMIC-HF Expansion StudyOctober 27, 2015 8:01 AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart FailureOctober 27, 2015 8:01 AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart FailureOctober 27, 2015 8:00 AM